1. FDA News Release: FDA approves new treatment for cystic fibrosis. Updated 8 July 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm (accessed 17 Jul 2015).
2. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR;Wainwright;N Engl J Med,2015
3. Pulmonary-Allergy Drugs Advisory Committee. FDA briefing document, NDA# 206038: for lumacaftor/ivacaftor combination oral tablets for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 12 May 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM446193.pdf (accessed 20 May 2015).
4. Vertex. Sponsor briefing document for the FDA Pulmonary-Allergy Drugs Advisory Committee: Orkambi (Lumacaftor/Ivacaftor) for the treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene: NDA 206038. 6 April 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM446195.pdf (accessed 20 May 2015).
5. FDA presentation slides for the May 12, 2015 meeting of the Pulmonary-Allergy Drugs Advisory Committee. 12 May 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM447292.pdf. (accessed 20 May 2015).